University of Thi-Qar Journal of Science (UTJsci)
E-ISSN: 2709-0256, P-ISSN: 1991-8690, Vol. 10, No. 2, Dec. 2023

A Review of Asprosin as new Biomarker for diagnosis different Diseases

1st Safaa Ehssan Atta
National Diabetes Center
Mustansiriyah University.
Baghdad / Iraq
safaaehssan@uomustansiriyah.edu.iq

2nd Baydaa Ahmed Abed
National Diabetes Center
Mustansiriyah University.
Baghdad/ Iraq
baydaaahmed@yahoo.com

3rd Isam Noori Salman
National Diabetes Center
Mustansiriyah University.
Baghdad / Iraq
esam.kirwi@yahoo.com

4th Lujain A. Ghannawi
National Diabetes Center
Mustansiriyah University.
Baghdad / Iraq
lujain.aljubory20@yahoo.com

Received: 2023-10-08, Revised: 2023-11-01, Accepted: 2023-11-04, Published: 2023-12-28

***Abstract*—This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer)-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifested in several cases and illnesses Asprosin hormone is newly adipokine helps the liver produce glucose. White adipose tissue secretes the novel hormone asprosin, which stimulates the release of hepatic glucose, making protein a possible target for new treatments for obesity and type 2 diabetes mellitus. Exons (65 and 66) of the gene(Fibrillin 1 (FBN1)), which was recently shown to be a new hormone released by white adipose tissues, are the final two exons that code for asprosin. However, further research is needed to fully understand how asprosin affects pancreatic beta-cells, leading to pathologically elevated cellular dysfunction and inflammation. Asprosin hormone is raised in human with metabolic disease. The findings imply that asprosin hormone may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including CVDs, obesity, T2DM, cancer, hypothyroidism, and PCOS. Depleting asprosin or attenuating its activity may potentially offer a novel therapeutic option for the treatment of T2DM and obesity.**

***Keywords*—Asprosin, diabetes mellitus, Cardiovascular diseases, obesity, FBN1.**

I. INTRODUCTION

A new adipokine is called asprosin that is a circulating hormone and mostly released by white adipose tissue (WAT). According to earlier research, asprosin affects insulin resistance, glucose tolerance, and fasting-induced homeostasis [1]. The Fibrillin1 gene (FBN1), the precursor of a recently identified glucogenic hormone, encodes for asprosin [2, 3]. The previous studies verified the greatest expression levels in WAT of mice and humans after analyzing FBN1 mRNA expression, indicating the crucial role of (Fbn1) in adipogenesis [4]. In a study of newborns premature aging (NPS), Romere et al., first discovered asprosin as a novel glucogenic protein adipokine in (2016). Exons (65 and 66) of FBN1 gene, which code for asprosin. Despite having significantly lower plasma insulin levels in the (NPS) patients. whose (FBN1) truncating mutation renders them asprosin-deficient, maintained euglycemia. In addition to eating less and being fairly thin, the (NPS) patients. The probable effects of asprosin on lipid and carbohydrate metabolism are indicated by all of these abnormalities. Asprosin functions intricately in the organs, and central nervous system (CNS). It affects cell apoptosis, insulin resistance, glucose metabolism, and hunger [5].

The disturbance of the regular metabolic processes is primarily responsible for metabolic diseases including obesity, coronary vascular disease, POLY-CYSTIC ovaries syndrome (PCOS), and diabetes. Asprosin has a crucial and intricate function in metabolism and METABOLIC illnesses, according to a recent study. Asprosin has a crucial and essential function in metabolic disorders and metabolism [6]. In order to act in the brain, asprosin can also leave the circulation and pass the blood-brain barrier (Fig. 1). The discovery of asprosin in the cerebrospinal fluid (CSF) of rats at quantities (5- to 10) fold lower than in plasma was the first proof that it was a cerebrospinal fluid (CSF) protein in addition to being a plasma protein. Fasting elevated CSF asprosin levels similar to plasma.

https://doi.org/10.32792/utq/utjsci/v10i2.1125

Additionally, asprosin administered intravenously demonstrated a striking capacity to pass the blood-brain barrier and reach the CSF [7].

II. Asprosin function

Asprosin is released into circulation in mice and human at a nanomolar quantity. In the liver, asprosin induces the release and synthesis of glucose, which activates the Cyclic adenosine-Mono-Phosphate (cAMP) signaling flow through the unidentified (G protein-coupled receptor (GPCR)) and increases hunger in the hypothalamus [8].

III. Mechanism of asprosin action

After being secreted, asprosin travels through the bloodstream before being drawn in by the liver, where it attaches to the surface of hepatocytes and stimulates blood glucose increase, a necessary condition for life and proper brain function [1]. Asprosin enters the liver and the brain after being released from white adipose tissue. Asprosin has a glucogenic action in the liver via activating the olfactory (G-protein-coupled receptor). Asprosin increases hunger in the brain by activatingorexigenic(AgRP) neurons via receptor and subtly suppressinganorexigenic(POMC) neurons [7].



Figure 1: mechanism of asprosin action[7].
Note: Plasma agouti-related protein (AgRP) ;Pro-opiomelanocortin (POMC); Gamma-aminobutyric acid (GABA); olfactory receptor (OLFR734) and olfactory receptor family 4 subfamily M member 1 (OR4M1).

IV. Asprosin and disease

A. *Inflammation:*

Through the development of inflammation, persistently non-esterified fatty acids and elevated blood glucose cause pancreatic β-cells malfunction and apoptosis,[9]. OBESITY-ASSOCIATED with abnormally high blood free fatty acids that result in c-Jun N-terminal kinase and oxidative stress, which lead to promoted inflammation [10]. Therefore, by maintaining pancreatic β-cells , effective inflammation control may be a therapeutic strategy for treating type 2 diabetes. In fact, recent clinical investigations have shown that reducing inflammation reduces type 2 diabetes by increasing insulin production from -cells and improving hyperglycemiaContrarily, circulating pro-inflammatory cytokines such interferon gamma, tumor necrosis factor alpha(TNFα) and interleukin 1 beta (IL-1), decrease β-cell insulin secretion by impairing calcium flow. Additionally, TNFα causes inflammation in β-cell, which leads to β-cell apoptosis through the accumulation of (islet amyloid polypeptide) [8,11].

B. *Cardiovascular diseases (CVDs):*

Over the past 30 years, the number of common cases has doubled, and death rates have been steadily climbing, cardiovascular diseases (CVDs) continue to be the major contributor to the worldwide burden of illnesses [12]. Adipokines, bioactive substances and cytokines derived from adipose tissue can control glucose and lipid metabolism and play a part in the onset and progression of CVDs. Some adipokines have protective effects against CVDs, while others have negative effects. Other adipokines, however, affect CVDs differently depending on the conditions [13]. In cases of CVD, diabetes ,obesity , and metabolic syndrome, asprosin may be used as a means of diagnosis and a treatment. The asprosin receptors, functions , and structure are discussed , along with how they relate to CVDs. Adipocytokines have a significant role in the pathophysiology of CVDs by controlling insulin sensitivity and secretion [14]. The development of CVDs and insulin resistance is aided by the angiopoietin-like 4 (ANGPTL4) and adipokines asprosin. In light of this, we proposed that plasma levels of ANGPTL4 and asprosin are related to atherosclerosis and early stages of insulin resistance [15]. A significant function for asprosin and ANGPTL4 in the development of insulin resistance Inducing cardiac ANGPTL4 gene expression guarded the heart against oxidative stress brought on by fatty acids[16, 17].

C. *diabetes mellitus*

Asprosin hormone is a new protein that secretes WAT and the ability to trigger the release of hepatic glucose [18]. The asprosin level was reported to rise in Three kinds of diabetes mellitus (DM). In patients newly diagnosed DM Following a 24-week course of treatment, a hypoglycemic drug sodium-glucose co-transporter-2 (SGLT2) inhibitors, that specifically inhibits glucose reabsorption, considerably reduce the amount of asprosin in the blood)[19]. Circulating asprosin in healthy adults exhibits diurnal oscillation with an abrupt decline that coincides with the start of eating[20].

The level of asprosin is positively correlated in T2DM patients with homeostasis model assessment for insulin resistance (HOMA-IR) hemoglobin A1c, fasting blood glucose (FBG)[21,22]. Lipid metabolism and serum asprosin are closely related to the fact that TG and concentrations of asprosin were positively associated. In T2DM patients, TG and asprosin were associated independently. Dyslipidemia is a prevalent condition in the insulin-resistant liver, where it is accompanied by increased hepatic glucose production in diabetic patients [18, 23].

D. Obesity

With the improvement in people's living standards and unhealthy lifestyles, obesity and obesity-related illnesses including T2DM are rapidly rising globally [11]. Therefore, insulin resistance and hyperinsulinemia are linked to obesity [24]. The asprosin hormone, which also has a central action, stimulates ultimately, appetite causing weight gain and obesity [3, 25]. Obesity is a pathological condition that increases the risk of several illnesses, includingcardiovascular disease, T2DM, some types of the cancer, and fatty liver disease [26]. Adipose tissue functions as an organ to energy storage and secretespeptides, lipids, adipokines, and cytokines that control the metabolism of the heart, liver, central nervous system, and muscles. Asprosin may have more complicated activities than only controlling hunger and weight, since higher asprosin concentrations in obese persons before bariatric surgery were linked to greater weight loss after surgery [27].

E. Thyroid

Thyroid hormones play crucial roles insignaling processes, energy-regulating mechanisms, and healthy development that have an impact on how much energy is used through both peripheral pathways and central [28]. One of the major signs and symptoms of hypothyroidism is weight gain. This is directly related to a rise in the body's overall mass of fat[29]. Asprosin is increased in patients with hypothyroidism and (T2DM with hypothyroidism)(1). Changes in the thyroid profile can affect asprosin secretion, which can cause further problems when there is too much visceral adipose tissue[30].

F. Polycystic ovary syndrome

Energy turbulence is a gynecological illness known as polycystic ovary syndrome (PCOS). According to the information that is currently available, the etiopathology of PCOS may be influenced by considerably rising asprosin levels in the blood. Asprosin levels is rise, providing fresh insight into PCOS-related alterations in the reproductive endocrinology and maybe giving light on the pathogenesis of PCOS [31].
found that asprosin decreases insulingrowth factor 1(IGF-1) induced cell proliferation and enhances luteinizing hormone(LH) induced cell androstenedione synthesis, indicating that the novel hormone may control ovarian follicle activity[32]. The PCOS-afflicted study ladies showed the typical concurrent endocrine and metabolic changes for this specific illness. Asprosin levels in women of reproductive age with PCOS are considerably higher. Alterations in asprosin production suggest that WAT might play a role in the development and maintenance of PCOS-related metabolic changes and abnormal insulin secretion and steroid hormone [32].

G. Cancer

Despite the fact that FBN1 mutations have been implicated in a number of studies as the root cause of (Marfan syndrome(MFS)), which is also linked to a higher risk of tumorigenesis. About the function of FBN1 mutations in cancer, very little is known[33,34]. Comparing the downregulation of (FBN1) in this cohort of tumors to the upregulation in other malignancies may indicate tissue-specific expression. According to a prior study, the main promoter of (FBN comprises a single(CpG-rich) region and is largely conserved in mammals [35-37].

V. ASPROSIN SIGNALING PATHWAYS IN DIFFERENT ORGANS.

obesity, diabetes, and the metabolic syndrome (MetS) are all directly linked tothe chronic inflammation. A saturated fatty acid called palmitate promotes inflammation and IR in peripheral tissue. Asprosin was significantly expressed in mice insulinomas after palmitate treatment, and cell viability and insulin secretion were also decreased [8]. Tumor necrosis factoralpha (TNF-), monocyte chemoattractant protein-1(MCP-1), nuclear factorkappa-light-chain-enhancer of activated B cells(NF-B) phosphorylation, apoptosis, and decreased insulinproduction were all brought on by this medication[11]. Additionally, apoptosis, islet -cell dysfunction, and asprosin induced inflammation, and through the activation of (toll-like receptor 4 (TLR4)) expression and the phosphorylation [11]. Additionally, asprosin demonstrated the activation in (endoplasmic reticulum (ER)) inflammation /stress pathways linked to (protein kinase C (PKC)) in skeletal muscle, which impairs insulin sensitivity [38].

A. Asprosin and liver :-

Asprosin enhanced glucose synthesis in the liver by activating the (cyclic adenosine monophosphate(cAMP)/protein kinaseA(PKA) pathway through the G-protein coupled receptor (OR4M1) in human [39].

B. Asprosin and pancreas:-

Through the stimulation of toll-like receptor4 (TLR4) expression and(c-Jun N-terminal kinases (JNK)) phosphorylation in the pancreas, asprosin encourages apoptosis, islet -cell malfunction, , and inflammation[40].

C. *Asprosin and skeletal muscle:-*

Through the activation of ER inflammation /stress pathways linked to (protein kinaseC-delta) (PKC-delta), skeletal muscle experienced decreased insulin sensitivity[41].

D. *Asprosin and adipocyte:-*

Inhibiting the (nuclear factor erythroid2-related factor 2) (Nrf2) pathway caused asprosin overexpression in adipocytes and speed up the lipid deposition process[42].

E. *Asprosin and mesenchymal stromal cells:-*

Through the elevation of (superoxide dismutase2) (SOD2)expression and activation of the (extracellular signal-regulated kinas1/2) (ERK1/2)-SOD2pathway, asprosin controls the function of (mesenchymal stromal cells) (MSC) against apoptosis and ROS production[8].

.



FIGURE2: SIGNALING PATHWAYS OF ASPROSIN IN THE DIFFERENT ORGANS[8].

VI. CONCLUSIONS

Asprosin hormone is raised in human with metabolic disease.The findings imply that asprosin hormone may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including (CVDs, obesity, T2DM, cancer, hypothyroidism, and PCOS). Depleting asprosin or attenuating, its activity may potentially offer a novel therapeutic option for treating T2DM and obesity.

ACKNOWLEDGMENT

We want to thank all the researchers and doctors at the National Diabetes Center at Mustansiriyah University who participated in writing and providing resources for this manuscript.

CONFLICT OF INTEREST

Authors declare that they have no conflict of interest.

REFERENCES

[1] N. Ateah, A. Y. Abed, and B. A. Abed, "Evaluation of Asprosin Hormone in Hypothyroidism Patients," Ibn AL-Haitham Journal For Pure and Applied Sciences, vol. 36, no. 2, pp. 224-231, 2023.

[2] L. Lönnqvist, D. Reinhardt, L. Sakai, and L. Peltonen, "Evidence for furin-type activity-mediated C-terminal processing of profibrillin-1 and interference in the processing by certain mutations," Human molecular genetics, vol. 7, no. 13, pp. 2039-2044, 1998.

[3] C. Duerrschmid et al., "Asprosin is a centrally acting orexigenic hormone," Nature medicine, vol. 23, no. 12, pp. 1444-1453, 2017.

[4] M. R. Davis et al., "Datasets of genes coexpressed with FBN1 in mouse adipose tissue and during human adipogenesis," Data in brief, vol. 8, pp. 851-857, 2016.

[5] C. Romere et al., "Asprosin, a fasting-induced glucogenic protein hormone," Cell, vol. 165, no. 3, pp. 566-579, 2016.

[6] M. Yuan, W. Li, Y. Zhu, B. Yu, and J. Wu, "Asprosin: a novel player in metabolic diseases," Frontiers in endocrinology, vol. 11, p. 64, 2020.

[7] J. G. Hoffmann, W. Xie, and A. R. Chopra, "Energy regulation mechanism and therapeutic potential of asprosin," Diabetes, vol. 69, no. 4, pp. 559-566, 2020.

[8] M. Farrag et al., "Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects," Frontiers in Endocrinology, vol. 13, p. 1101091, 2023.

[9] J. Montane, L. Cadavez, and A. Novials, "Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes," Diabetes, metabolic syndrome and obesity: targets and therapy, pp. 25-34, 2014.

[10] D. H. van Raalte and M. Diamant, "Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?," Diabetes research and clinical practice, vol. 93, pp. S37-S46, 2011.

[11] T. Lee, S. Yun, J. H. Jeong, and T. W. Jung, "Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation," Molecular and cellular endocrinology, vol. 486, pp. 96-104, 2019.

[12] G. A. Roth et al., "Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study," Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982-3021, 2020.

[13] L. Zhang, C. Chen, N. Zhou, Y. Fu, and X. Cheng, "Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride," Clinica chimica acta, vol. 489, pp. 183-188, 2019.

[14] M.-S. Wen et al., "The role of Asprosin in patients with dilated cardiomyopathy," BMC Cardiovascular Disorders, vol. 20, no. 1, pp. 1-8, 2020.

[15] W. H.-h. L. Wan-ying1Lin, M. L. X.-j. X. Guang-da, and S. d Triganti, "page (Original article)."

[16] L. J. McCulloch, L. R. Bramwell, B. Knight, and K. Kos, "Circulating and tissue specific transcription of angiopoietin-like protein 4 in human Type 2 diabetes," Metabolism, vol. 106, p. 154192, 2020.

[17] W. Hao-Hua, L. Wan-Ying, L. Min, L. Xiao-Jing, G.-D. Xiang, and S. D TRIGANTI, "Plasma asprosin,

CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease," Physiological Research, vol. 70, no. 2, p. 203, 2021.

[18] Z. Zhang, L. Zhu, Z. Wang, N. Hua, S. Hu, and Y. Chen, "Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review," Progress in Lipid Research, vol. 91, p. 101240, 2023.

[19] L. Liu et al., "The effects of asprosin on exercise-intervention in metabolic diseases," Frontiers in physiology, vol. 13, p. 907358, 2022.

[20] X. Zhang, H. Jiang, X. Ma, and H. Wu, "Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus," Journal of diabetes investigation, vol. 11, no. 2, pp. 349-355, 2020.

[21] X. Li et al., "Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases," Mediators of inflammation, vol. 2018, 2018.

[22] Y. Wang et al., "Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion," Mediators of inflammation, vol. 2018, 2018.

[23] A. T. M. ALSAJRI, "EXPLORATION OF THE RELATIONSHIP BETWEEN ASPROSIN WITH OXIDATIVE STRESS INDEX IN OBESE IRAQI PATIENTS," ÇANKIRI KARATEKİN UNIVERSITY, 2022.

[24] A. Elnagar, H. I. El-Belbasi, I. F. Rehan, and K. El-Dawy, "Asprosin: a novel biomarker of type 2 diabetes mellitus," Veterinary medicine in-between health & economy, vol. 55, no. 20, pp. 333-347, 2018.

[25] D. Corica et al., "Asprosin serum levels and glucose homeostasis in children with obesity," Cytokine, vol. 142, p. 155477, 2021.

[26] Y. Miao, H. Qin, Y. Zhong, K. Huang, and C. Rao, "Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue," The Journal of endocrinology, vol. 249, no. 2, p. 83, 2021.

[27] H. Nakhaei, M. Mogharnasi, and H. Fanaei, "Effect of swimming training on levels of asprosin, lipid profile, glucose and insulin resistance in rats with metabolic syndrome," Obesity medicine, vol. 15, p. 100111, 2019.

[28] R. Mogulkoc, D. Dasdelen, S. B. Baltaci, A. K. Baltaci, and A. Sivrikaya, "The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats," Hormone Molecular Biology and Clinical Investigation, vol. 42, no. 1, pp. 37-42, 2020.

[29] M. Kantorowicz, J. Szymura, Z. Szygula, J. Kusmierczyk, M. Maciejczyk, and M. Wiecek, "Nordic walking at maximal fat oxidation intensity decreases circulating asprosin and visceral obesity in women with metabolic disorders," Frontiers in Physiology, vol. 12, p. 726783, 2021.

[30] L. H. Al-Sultan and Y. A. Al-Issa, "Estimation of adropin hormone in Iraqi hypothyroidism patients with obesity," Acta Biomed, vol. 94, no. 2, p. e2023100, 2023.

[31] R. Deniz et al., "Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome," Journal of Obstetrics and Gynaecology, vol. 41, no. 2, pp. 279-284, 2021.

[32] F. R. Pérez-López, M. T. López-Baena, G. R. Pérez-Roncero, P. Chedraui, S. R. Varikasuvu, and P. García-Alfaro, "Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis," Gynecological Endocrinology, vol. 39, no. 1, p. 2152790, 2023.

[33] C.-W. Hsu et al., "Association between malignancies and Marfan syndrome: a population-based, nested case–control study in Taiwan," BMJ open, vol. 7, no. 10, p. e017243, 2017.

[34] S. E. ATTA and E. D. SALMAN, "Molecular Study of Fluoroquinolones Resistance Staphylococcus Aureus Isolated from Different Clinical Sources," *International Journal of Pharmaceutical Research (09752366),* vol. 12, no. 3, 2020.

[35] K. M. Summers et al., "Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1," Genomics, vol. 94, no. 4, pp. 233-240, 2009.

[36] J. Millstein et al., "Prognostic gene expression signature for high-grade serous ovarian cancer," Annals of Oncology, vol. 31, no. 9, pp. 1240-1250, 2020.

[37] R. Kerslake et al., "A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer," Oncology letters, vol. 22, no. 3, pp. 1-14, 2021.

[38] T. W. Jung et al., "Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle," Journal of cellular physiology, vol. 234, no. 11, pp. 20888-20899, 2019.

[39] E. Li *et al.*, "OLFR734 mediates glucose metabolism as a receptor of asprosin," *Cell metabolism*, vol. 30, no. 2, pp. 319-328. e8, 2019.

[40] M. M. Aboudounya and R. J. Heads, "COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation," Mediators of inflammation, vol. 2021, pp. 1-18, 2021.

[41] Y. Lin, M. Jiang, W. Chen, T. Zhao, and Y. Wei, "Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response," Biomedicine & Pharmacotherapy, vol. 118, p. 109249, 2019.

[42] N. A. Lefta, A. Y. Abed, and B. A. Abed, "Estimation of Asprosin Levels in Female Iraqi Patients with Type 2 Diabetes and Hypothyroidism," *Journal of Medicinal and Chemical Sciences*, vol. 6, no. 2, pp. 433-439, 2023, doi: 10.26655/jmchemsci.2023.2.23.